-+ 0.00%
-+ 0.00%
-+ 0.00%

BioCopy publishes ValidaTe AI discovery platform preprint on bioRxiv

PUBT·08/17/2026 15:26:33
Listen to the news
BioCopy publishes ValidaTe AI discovery platform preprint on bioRxiv
  • BioCopy published a bioRxiv preprint detailing its ValidaTe AI discovery platform for TCR-mimic therapeutics.
  • ValidaTe cut experimentally confirmed off-target binding by about 90% versus a benchmark molecule in BioCopy’s MAGE-A4 program.
  • Preprint outlines a closed-loop workflow combining AI prediction with high-throughput validation, structural characterization, functional confirmation.
  • Haute Capital Partners is a BioCopy shareholder, participated in the Series A financing as a key investor.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haute Capital Partners Ltd. published the original content used to generate this news brief on August 17, 2026, and is solely responsible for the information contained therein.